Mink Therapeutics Inc (INKT)

NASDAQ
2.11
+0.05(+2.43%)
After Hours
2.06
-0.05(-2.37%)
- Real-time Data
  • Volume:
    21,769
  • Day's Range:
    2.06 - 2.26
  • 52 wk Range:
    1.09 - 22.16

INKT Overview

Prev. Close
2.06
Day's Range
2.06-2.26
Revenue
-
Open
2.09
52 wk Range
1.09-22.16
EPS
-1.1
Volume
21,769
Market Cap
71.27M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
469,643
P/E Ratio
-2.34
Beta
-
1-Year Change
-
Shares Outstanding
33,775,073
Next Earnings Date
Nov 30, 2022
What is your sentiment on Mink Therapeutics?
or
Market is currently closed. Voting is open during market hours.

Mink Therapeutics Inc News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Mink Therapeutics Inc Company Profile

Mink Therapeutics Inc Company Profile

Employees
33

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

Read More

Analyst Price Target

Average9.33 (+342.34% Upside)
High15
Low6
Price2.11
No. of Analysts3
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellSell
Technical IndicatorsStrong SellStrong SellSellStrong SellSell
SummaryStrong SellStrong SellStrong SellStrong SellSell